Eli Lilly reported positive topline results from two Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, evaluating retatrutide, a triple hormone receptor agonist for obesity and related conditions. In TRIUMPH-2, participants with obesity and type 2 diabetes achieved substantial weight loss across multiple doses and showed improved glycemic control at 80 weeks, while TRIUMPH-3 demonstrated even greater weight reductions and A1C improvements in those with severe obesity and cardiovascular disease. Across both studies, retatrutide also reduced cardiovascular risk factors such as triglycerides and non-HDL cholesterol, with safety data showing common gastrointestinal events but manageable discontinuation rates. Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027, and the company cited potential indications including obesity, knee osteoarthritis pain, and obstructive sleep apnea. The announcements have reinforced investor expectations for retatrutide as a leading obesity treatment, with the company continuing to pursue global regulatory submissions. Media coverage across outlets highlighted the strong trial outcomes and the path toward regulatory approval, underscoring a pivotal moment for Lilly’s obesity portfolio.